ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260928066 Date: September 28, 2026

To, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India **SCRIP CODE: 543275**	To, **National Stock Exchange of India Limited** 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India **SYMBOL: ANURAS**

Dear Sir/Madam,

Subject: Intimation of acquisition of equity shares of Bliss GVS Pharma Limited ("Bliss") under the share purchase agreement dated 23 May 2026 ("SPA") executed among Anupam Rasayan India Limited (the "Acquirer" or the "Company") and Narsimha Shibroor Kamath, Vibha Gagan Sharma, Shruti Vishal Rao, Gautam Rasiklal Ashra, Arjun Gautam Ashra and Gulbarga Trading and Investment Private Limited (collectively "Sellers") read with the deed of adherence dated 17 July 2026 executed between the Acquirer and Mates Visa Consultancy Private Limited (the "PAC") pursuant to the open offer (as defined below), and other acquisition of equity shares of Bliss.

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

This is in continuation of our intimations on 23 May 2026 and 17 July 2026, and has reference to the public announcement dated 23 May 2026 ("**Public Announcement**"), the detailed public statement dated 30 May 2026 ("**Detailed Public Statement**"), the draft letter of offer dated 8 June 2026 ("**Draft Letter of Offer**"), the addendum to the Public Announcement, Detailed Public Statement and Draft Letter of Offer dated 17 July 2026, the letter of offer dated 18 July 2026 ("**Letter of Offer**"), issued in relation to the open offer announced in accordance with Regulation 3(1) and 4 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("**Open Offer**").

Upon the closure of the tendering period and the completion of payment of consideration, all 1,669 equity shares validly tendered by eligible public shareholders in the Open Offer (representing 0.00% of the equity share capital of Bliss) were credited to the demat account of the Acquirer on 24 August 2026. The relevant documents in relation to the Open Offer are available here.

Further, today, on 28 September 2026, the Company has acquired further 22,50,000 (Twenty Two Lakh Fifty Thousand) equity shares of Bliss through an on-market transaction. The details as required under Regulation 30 of the Listing Regulations read with Paragraph 1 of Part A of Schedule III of the Listing Regulations and paragraph 1 of Annexure 18 of the SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (as amended) ("**SEBI Master Circular**"), for the acquisition of 22,50,000 (Twenty Two Lakh Fifty Thousand) equity shares of Bliss has been set out in **Annexure A**.

Pursuant to the consummation of the transaction contemplated in the SPA (i.e., the Underlying Transaction (*as defined in the Letter of Offer*)) on 28 September 2026, the Acquirer has completed the acquisition of 5,09,84,595 equity shares of Bliss, representing 47.95% of the equity share capital of Bliss. For more information on the Underlying Transaction, please refer to paragraphs 7 to 9 of Part A (Background to the

Open Offer) of Section III (Details of the Open Offer) of the Letter of Offer, available here and the disclosure made by the Company on 23 May 2026, available here.

Following the aforesaid acquisitions, together with 1,699 equity shares of Bliss acquired by the PAC pursuant to the Open Offer, the Acquirer and the PAC collectively hold an aggregate of 5,32,36,264 equity shares of Bliss, representing 50.07% of the equity share capital of Bliss.

Accordingly, the Acquirer and the PAC have acquired control of Bliss and have been designated as 'promoters' of Bliss with effect from 28 September 2026. In this regard, please note the disclosure made by Bliss regarding the outcome of the meeting of its board of directors held today on 28 September 2026 available here, wherein the board of directors of Bliss have *inter alia* noted (i) the change of control of Bliss; and, (ii) the designation of Acquirer and the PAC as promoters of Bliss.

This intimation will also be hosted on the website of the Company at www.anupamrasayan.com.

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

ASHISH GUPTA Digitally signed by ASHISH GUPTA Date: 2026.09.29 00:00:32 +05'30'

Ashish Gupta
Company Secretary & Compliance Officer

Encl.: As above

Annexure A

Details pursuant to Clause 1 of Para A of Part A of Schedule III of the Listing Regulations read with Para 1, Annexure 18 of the SEBI Master Circular

S. No.	Particulars	Details
1.	**Name of the target entity, details in brief such as size, turnover etc.;**	Bliss GVS Pharma Limited ("Target Company") is a public listed company primarily engaged in the business of manufacturing of pharmaceutical products including suppositories, pessaries, tablets, capsules, and other specialty pharmaceutical products. • Turnover of the Target Company as on March 31, 2026 (on a consolidated basis): Rs. 1000,64,26,000 • Net worth of the Target Company as on March 31, 2026 (on a consolidated basis): Rs. 1231,76,00,000
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No. The Alternate Transaction does not fall within the definition of a related party transaction. Further, the promoter/ promoter group/ group companies of the Company do not have any interest in the Target Company.
3.	No. The Alternate Transaction does not fall within the definition of a related party transaction. Further, the promoter/ promoter group/ group companies of the Company do not have any interest in the Target Company.	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Company's proposed acquisition of the Target Company would strategically strengthen the Company's presence across the pharmaceutical value chain, spanning KSMs to finished dosage formulations. The Target Company's established capabilities

Registered Office:
Office Nos. 1101 to 1107, 11th Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Surat-395007, Gujarat, India.

Tel. : +91-261-2398991-95
Fax : +91-261-2398996
E-mail : office@anupamrasayan.com
Website : www.anupamrasayan.com
CIN - L24231GJ2003PLC042988

		in niche dosage forms, differentiated brands, strong international footprint, and expertise across multiple therapeutic segments, combined with the Company's advanced chemistry capabilities, would create a more integrated and diversified pharmaceutical manufacturing platform. The acquisition is expected to enhance forward integration and unlock significant synergies through innovation and operational efficiencies, thereby supporting sustainable long-term growth and value creation.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	The acquisition of additional securities has been completed today (28 September 2026).
7.	Consideration - whethercash consideration or share swap or any other form and details of the same;	Cash Consideration Aggregate consideration: INR 162,73,98,675.00 (Indian Rupees One Hundred Sixty Two Crores Seventy Three Lakhs Ninety Eight Thousand Six Hundred Seventy Five), excluding levies and transaction costs
8.	Cost of acquisition and/or the price at which the shares are acquired;	The equity shares have been acquired at a price of Rs. 723.2883 (Rupees Seven Hundred Twenty Three point two eight eight three) per equity share.
9.	Percentage of shareholding/control acquired and/or number of shares acquired;	22,50,000 (Twenty Two Lakh Fifty Thousand) equity shares representing approximately 2.12% of the paid-up equity share capital of the Target Company.

<table>
<tr><td>10.</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).</td><td>The Target Company is a public listed company incorporated under the provisions of the Companies Act, 1956 on 11 December 1984.

The Target Company is engaged in the business of manufacturing of pharmaceutical products including suppositories, pessaries, tablets, capsules, and other specialty pharmaceutical products.

The Target Company has a global footprint in over 60+ countries with its most dominant market being SubSaharan Africa.

Last three years' turnover:
<table><tr><th>FY</th><th>Turnover</th></tr><tr><td>FY 2023-24</td><td>Rs.1000,64,26,000</td></tr><tr><td>FY 2024-25</td><td>Rs. 846,21,97,000</td></tr><tr><td>FY 2025-26</td><td>Rs. 798,98,23,000</td></tr></table></td></tr>
</table>

Registered Office:
Office Nos. 1101 to 1107, 11th Floor, Icon Rio,
Behind Icon Business Centre, Dumas Road,
Surat-395007, Gujarat, India.

Tel. : +91-261-2398991-95
Fax : +91-261-2398996
E-mail : office@anupamrasayan.com
Website : www.anupamrasayan.com
CIN - L24231GJ2003PLC042988